1
|
Dumit S, Avtandilashvili M, McComish SL, Miller G, Swanson J, Tolmachev SY. Modeling Plutonium Decorporation in a Female Nuclear Worker Treated with Ca-DTPA after Inhalation Intake. HEALTH PHYSICS 2024:00004032-990000000-00170. [PMID: 39037363 DOI: 10.1097/hp.0000000000001859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/23/2024]
Abstract
ABSTRACT The present work models plutonium (Pu) biokinetics in a female former nuclear worker. Her bioassay measurements are available at the US Transuranium and Uranium Registries. The worker was internally exposed to a plutonium-americium mixture via acute inhalation at a nuclear weapons facility. She was medically treated with injections of 1 g Ca-DTPA on days 0, 5, and 14 after the intake. Between days 0 and 20, fecal and urine samples were collected and analyzed for 239Pu and 241Am. Subsequently, she was followed up for bioassay monitoring over 14 y, with additional post-treatment urine samples collected and analyzed for 239Pu. The uniqueness of this dataset is due to the availability of: (1) both early and long-term bioassay data from a female with plutonium intake; (2) data on chelation therapy for a female; and (3) fecal measurement results. Chelation therapy with Ca- and/or Zn-salts of DTPA is known to aid in reducing the internal radiation dose by enhancing the excretion of plutonium and americium from the body. Such enhancement affects plutonium biokinetics in the human body, posing a challenge to the internal dose assessment. The current radiation dose assessment practice is to exclude the data affected by Ca-DTPA from the analysis. The present analysis is the first to explicitly model the chelation-affected bioassay data in a female by using a newly developed chelation model. Thus, the bioassay data collected during and after the Ca-DTPA administrations were used for biokinetic modeling and dose assessment. The Markov Chain Monte Carlo method was used to investigate model parameter uncertainty, based on the bioassay data and assumed prior probability distributions. A χ2/nData (number of data points) ≈ 1 was observed in this study, which indicates self-consistency of the data with the model. Results of this study show that the worker's 239Pu intake was 12 Bq, with a committed effective dose to the whole-body of 1.2 mSv and a committed equivalent dose to the bone surfaces, liver, and lungs of 37.8, 9.1, and 0.8 mSv, respectively. This study also discusses the worker's dose reduction due to chelation treatment.
Collapse
Affiliation(s)
- Sara Dumit
- Los Alamos National Laboratory (LANL), Los Alamos, NM 87545
| | - Maia Avtandilashvili
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| | - Stacey L McComish
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| | | | | | - Sergey Y Tolmachev
- United States Transuranium and Uranium Registries (USTUR), College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Richland, WA 99354
| |
Collapse
|
2
|
Mate-Kole EM, Dewji SA. Mathematical complexities in radionuclide metabolic modelling: a review of ordinary differential equation kinetics solvers in biokinetic modelling. JOURNAL OF RADIOLOGICAL PROTECTION : OFFICIAL JOURNAL OF THE SOCIETY FOR RADIOLOGICAL PROTECTION 2024; 44:021001. [PMID: 38324906 PMCID: PMC11214694 DOI: 10.1088/1361-6498/ad270d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 01/26/2024] [Accepted: 02/07/2024] [Indexed: 02/09/2024]
Abstract
Biokinetic models have been employed in internal dosimetry (ID) to model the human body's time-dependent retention and excretion of radionuclides. Consequently, biokinetic models have become instrumental in modelling the body burden from biological processes from internalized radionuclides for prospective and retrospective dose assessment. Solutions to biokinetic equations have been modelled as a system of coupled ordinary differential equations (ODEs) representing the time-dependent distribution of materials deposited within the body. In parallel, several mathematical algorithms were developed for solving general kinetic problems, upon which biokinetic solution tools were constructed. This paper provides a comprehensive review of mathematical solving methods adopted by some known internal dose computer codes for modelling the distribution and dosimetry for internal emitters, highlighting the mathematical frameworks, capabilities, and limitations. Further discussion details the mathematical underpinnings of biokinetic solutions in a unique approach paralleling advancements in ID. The capabilities of available mathematical solvers in computational systems were also emphasized. A survey of ODE forms, methods, and solvers was conducted to highlight capabilities for advancing the utilization of modern toolkits in ID. This review is the first of its kind in framing the development of biokinetic solving methods as the juxtaposition of mathematical solving schemes and computational capabilities, highlighting the evolution in biokinetic solving for radiation dose assessment.
Collapse
Affiliation(s)
- Emmanuel Matey Mate-Kole
- Nuclear and Radiological Engineering and Medical Physics Programs, Georgia Institute of Technology, Atlanta, GA, United States of America
| | - Shaheen Azim Dewji
- Nuclear and Radiological Engineering and Medical Physics Programs, Georgia Institute of Technology, Atlanta, GA, United States of America
| |
Collapse
|
3
|
Reis A, Sampaio C, Sousa W, Aguiar L, Bertelli L. Key topics for making decisions on decorporation terapies. RADIATION PROTECTION DOSIMETRY 2024; 200:707-714. [PMID: 38678315 DOI: 10.1093/rpd/ncae097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 01/19/2024] [Accepted: 04/08/2024] [Indexed: 04/29/2024]
Abstract
Decorporation therapies increase the excretion of the incorporated material and therefore may reduce the probability of the occurrence of stochastic effects and may avoid deterministic effects in persons internally contaminated with radionuclides. The decision to initiate decorporation therapy should consider the effects of treatment in relation to the benefit provided. The literature presents threshold values above which treatment is recommended. The objective of this work is to collect and summarize recommendations on decorporation therapy. Ten key topics are presented for consideration by a multidisciplinary team when assessing the risk-benefit balance for performing decorporation therapy.
Collapse
Affiliation(s)
- Arlene Reis
- Institute of Radiation Protection and Dosimetry (IRD), Division of Dosimetry and Radiation Protection, Barra da Tijuca, RJ 22783-127, Brazil
| | - Camilla Sampaio
- Institute of Radiation Protection and Dosimetry (IRD), Division of Dosimetry and Radiation Protection, Barra da Tijuca, RJ 22783-127, Brazil
| | - Wanderson Sousa
- Institute of Radiation Protection and Dosimetry (IRD), Division of Dosimetry and Radiation Protection, Barra da Tijuca, RJ 22783-127, Brazil
| | - Laís Aguiar
- Institute of Radiation Protection and Dosimetry (IRD), Division of Dosimetry and Radiation Protection, Barra da Tijuca, RJ 22783-127, Brazil
| | - Luiz Bertelli
- L Bertelli & Associates, 6190 S Eagle Nest Drive Murray, UT, 84123, USA
| |
Collapse
|
4
|
Dumit S, Miller G, Grémy O, Poudel D, Bertelli L, Klumpp JA. Chelation Modeling of a Plutonium-238 Inhalation Incident Treated with Delayed DTPA. Radiat Res 2023; 200:577-586. [PMID: 37956868 DOI: 10.1667/rade-23-00135.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 10/14/2023] [Indexed: 11/15/2023]
Abstract
This work describes an analysis, using a previously established chelation model, of the bioassay data collected from a worker who received delayed chelation therapy following a plutonium-238 inhalation. The details of the case have already been described in two publications. The individual was treated with Ca-DTPA via multiple intravenous injections and then nebulizations beginning several months after the intake and continuing for four years. The exact date and circumstances of the intake are unknown. However, interviews with the worker suggested that the intake occurred via inhalation of a soluble plutonium compound. The worker provided daily urine and fecal bioassay samples throughout the chelation treatment protocol, including samples collected before, during, and after the administration of Ca-DTPA. Unlike the previous two publications presenting this case, the current analysis explicitly models the combined biokinetics of the plutonium-DTPA chelate. Using the previously established chelation model, it was possible to fit the data through optimizing only the intake (day and magnitude), solubility, and absorbed fraction of nebulized Ca-DTPA. This work supports the hypothesis that the efficacy of the delayed chelation treatment observed in this case results mainly from chelation of cell-internalized plutonium by Ca-DTPA (intracellular chelation). It also demonstrates the validity of the previously established chelation model. As the bioassay data were modified to ensure data anonymization, the calculation of the "true" committed effective dose was not possible. However, the treatment-induced dose inhibition (in percentage) was calculated.
Collapse
Affiliation(s)
- Sara Dumit
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| | - Guthrie Miller
- Unaffiliated (retired from Los Alamos National Laboratory), Santa Fe, New Mexico
| | - Olivier Grémy
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Deepesh Poudel
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| | | | - John A Klumpp
- Los Alamos National Laboratory (LANL), Radiation Protection Division, Los Alamos, New Mexico 87545
| |
Collapse
|
5
|
Kastl M, Grémy O, Lamart S, Giussani A, Li WB, Hoeschen C. Modelling DTPA therapy following Am contamination in rats. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2023; 62:483-495. [PMID: 37831188 PMCID: PMC10628027 DOI: 10.1007/s00411-023-01046-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 09/25/2023] [Indexed: 10/14/2023]
Abstract
A major challenge in modelling the decorporation of actinides (An), such as americium (Am), with DTPA (diethylenetriaminepentaacetic acid) is the fact that standard biokinetic models become inadequate for assessing radionuclide intake and estimating the resulting dose, as DTPA perturbs the regular biokinetics of the radionuclide. At present, most attempts existing in the literature are empirical and developed mainly for the interpretation of one or a limited number of specific incorporation cases. Recently, several approaches have been presented with the aim of developing a generic model, one of which reported the unperturbed biokinetics of plutonium (Pu), the chelation process and the behaviour of the chelated compound An-DTPA with a single model structure. The aim of the approach described in this present work is the development of a generic model that is able to describe the biokinetics of Am, DTPA and the chelate Am-DTPA simultaneously. Since accidental intakes in humans present many unknowns and large uncertainties, data from controlled studies in animals were used. In these studies, different amounts of DTPA were administered at different times after contamination with known quantities of Am. To account for the enhancement of faecal excretion and reduction in liver retention, DTPA is assumed to chelate Am not only in extracellular fluids, but also in hepatocytes. A good agreement was found between the predictions of the proposed model and the experimental results for urinary and faecal excretion and accumulation and retention in the liver. However, the decorporation from the skeletal compartment could not be reproduced satisfactorily under these simple assumptions.
Collapse
Affiliation(s)
- Manuel Kastl
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.
| | - Olivier Grémy
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
| | - Stephanie Lamart
- Laboratoire de Radio Toxicologie, CEA, Université de Paris-Saclay, Arpajon, France
- Laboratoire d'Evaluation de la Dose Interne, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SDOS/LEDI, Fontenay-aux-Roses, France
| | - Augusto Giussani
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Wei Bo Li
- Institute of Radiation Medicine, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Division of Medical and Occupational Radiation Protection, Federal Office for Radiation Protection, Oberschleißheim, Germany
| | - Christoph Hoeschen
- Institut für Medizintechnik, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany
| |
Collapse
|
6
|
Kontoghiorghes GJ. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. Pharmaceuticals (Basel) 2023; 16:1016. [PMID: 37513928 PMCID: PMC10384919 DOI: 10.3390/ph16071016] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/13/2023] [Accepted: 07/15/2023] [Indexed: 07/30/2023] Open
Abstract
The iron chelating orphan drug deferiprone (L1), discovered over 40 years ago, has been used daily by patients across the world at high doses (75-100 mg/kg) for more than 30 years with no serious toxicity. The level of safety and the simple, inexpensive synthesis are some of the many unique properties of L1, which played a major role in the contribution of the drug in the transition of thalassaemia from a fatal to a chronic disease. Other unique and valuable clinical properties of L1 in relation to pharmacology and metabolism include: oral effectiveness, which improved compliance compared to the prototype therapy with subcutaneous deferoxamine; highly effective iron removal from all iron-loaded organs, particularly the heart, which is the major target organ of iron toxicity and the cause of mortality in thalassaemic patients; an ability to achieve negative iron balance, completely remove all excess iron, and maintain normal iron stores in thalassaemic patients; rapid absorption from the stomach and rapid clearance from the body, allowing a greater frequency of repeated administration and overall increased efficacy of iron excretion, which is dependent on the dose used and also the concentration achieved at the site of drug action; and its ability to cross the blood-brain barrier and treat malignant, neurological, and microbial diseases affecting the brain. Some differential pharmacological activity by L1 among patients has been generally shown in relation to the absorption, distribution, metabolism, elimination, and toxicity (ADMET) of the drug. Unique properties exhibited by L1 in comparison to other drugs include specific protein interactions and antioxidant effects, such as iron removal from transferrin and lactoferrin; inhibition of iron and copper catalytic production of free radicals, ferroptosis, and cuproptosis; and inhibition of iron-containing proteins associated with different pathological conditions. The unique properties of L1 have attracted the interest of many investigators for drug repurposing and use in many pathological conditions, including cancer, neurodegenerative conditions, microbial conditions, renal conditions, free radical pathology, metal intoxication in relation to Fe, Cu, Al, Zn, Ga, In, U, and Pu, and other diseases. Similarly, the properties of L1 increase the prospects of its wider use in optimizing therapeutic efforts in many other fields of medicine, including synergies with other drugs.
Collapse
Affiliation(s)
- George J Kontoghiorghes
- Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus
| |
Collapse
|
7
|
Poudel D, Dumit S, Bertelli L, Miller G, Macsik Z, Klumpp J. Dose Assessment Following a 238 Pu Inhalation Incident at Los Alamos National Laboratory. HEALTH PHYSICS 2023; 124:88-96. [PMID: 36318044 DOI: 10.1097/hp.0000000000001628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
A glovebox breach at the plutonium facility at Los Alamos National Laboratory potentially exposed 15 individuals to 238 Pu aerosols. One of the individuals (P0) received two 1-g intravenous DTPA treatments, one on the day of the intake and another the following day. Several urine samples were collected from the individuals involved in the incident. Particle size analysis on the PPE and solubility analysis of the particles on a filter sample were conducted in vitro. The applicability of the results from the in vitro studies for dose assessment was questionable because of the effect of the cloth mask the workers were wearing for COVID-related protection. Based on several considerations, including the effect of cloth masks on the "effective" particle size inhaled and the analysis of fecal-to-urine ratio, the default Type M 1 μm AMAD model was used to estimate intakes and doses. Using the urinary excretion data collected after 100 d post last chelation treatment, the committed effective dose, E(50), for P0 was calculated to be 5.2 mSv. For all others, the bioassay data were consistent with no intakes or very small intakes [corresponding to E(50) less than 0.1 mSv].
Collapse
Affiliation(s)
- Deepesh Poudel
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | - Sara Dumit
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | - Luiz Bertelli
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| | | | - Zsuzsanna Macsik
- Nuclear and Radiochemistry, Los Alamos National Laboratory, Los Alamos, NM
| | - John Klumpp
- Radiation Protection Services, Los Alamos National Laboratory, Los Alamos, NM
| |
Collapse
|
8
|
Miller G, Dumit S, Poudel D, Klumpp J. Use of Nasal Swab Activity to Estimate Intake in Internal Dosimetry. HEALTH PHYSICS 2023; 124:125-128. [PMID: 36625836 DOI: 10.1097/hp.0000000000001646] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
In addition to a review of theoretical analyses, this work presents an empirical study of nasal swab data from the Los Alamos National Laboratory (LANL) database correlated with intake obtained from plutonium internal dosimetry calculations. As a result of this work, several "intake-versus-nasal-swab" models were derived. We advocate quantitative use of nasal swab measurements in dose assessment calculations and discuss ways that this can be done. The best description of the LANL plutonium internal dose database is arguably intake = A + Bx, where A = 2.7 Bq, B = 3.8, and x = summed nasal swab activity. The geometric standard deviation was found to be 8.2. This relationship, obtained using plutonium data, should apply also for other radionuclides.
Collapse
Affiliation(s)
- Guthrie Miller
- Unaffiliated (retired from Los Alamos National Laboratory), Santa Fe, NM
| | - Sara Dumit
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| | - Deepesh Poudel
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| | - John Klumpp
- Los Alamos National Laboratory, Radiation Protection Division, Los Alamos, NM 87545
| |
Collapse
|